AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

Paired with AMPEL’s pipeline of tools to analyze very large and complex clinical datasets (“Big Data”), FibroGENE® is a significant step towards implementing a routine test for monitoring fibromyalgia and providing decision support for treatment based on a patient’s gene expression. This will transform the way doctors treat fibromyalgia by using the information gathered by the lab test and analyzed by bioinformatics to characterize the precise molecular abnormalities and treat symptoms, reduce pain and increase the quality of life of millions of Americans. 

read more
One-Size-Fits-All COVID Policy Vs. Precision Medicine

One-Size-Fits-All COVID Policy Vs. Precision Medicine

What a revelation. It turns out that a person’s genes have a big influence over how or his or her immunological system responds to the COVID-19 virus. A Charlottesville company, Ampel Biosolutions, has developed a blood test, which it claims predicts with 90% accuracy if a COVID-infected patient is at risk for a serious, life-threatening case.

read more

Pin It on Pinterest